Therefore, the standard augmentation therapy recommended for patients with AATD is defined as 60 mg AAT/kg body weight (b.w.)per week reaching approximately 50% of serum AAT levels found in healthy individuals (19). Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.